• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

    10/4/24 5:01:03 PM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Augmedix, Inc. [ AUGX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/02/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/02/2024 D 16,421,788(1)(2) D $2.35 0 I See Footnote(3)
    Common Stock 10/02/2024 D 9,446,146(1)(2) D $2.35 0 D(4)
    Common Stock 10/02/2024 D 6,218,238(1)(2) D $2.35 0 D(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Pre-Funded Warrants to Purchase Common Stock $0.0001 10/02/2024 D 3,125,195(1)(2) (6) (6) Common Stock 3,125,195 (1)(2) 0 I See Footnote(3)
    Pre-Funded Warrants to Purchase Common Stock $0.0001 10/02/2024 D 3,125,195(1)(2) (6) (6) Common Stock 3,125,195 (1)(2) 0 D(4)
    Breakeven Warrants $1.75 10/02/2024 D 1,093,799(1)(2) (7) (7) Common Stock 1,093,799 (1)(2) 0 I See Footnote(3)
    Breakeven Warrants $1.75 10/02/2024 D 1,093,799(1)(2) (7) (7) Common Stock 1,093,799 (1)(2) 0 D(4)
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Green Jeremy

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC (NY OFFICE)
    45 W. 27TH STREET, FLOOR 11

    (Street)
    NEW YORK NY 10001

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    RedCo II Master Fund, L.P.

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC ONE LETTERMAN
    DRIVE, BUILDING D SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Redmile Private Investments II, L.P.

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC ONE LETTERMAN
    DRIVE, BUILDING D SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On October 2, 2024, the Issuer completed its previously announced merger transaction with Commure, Inc. ("Parent") and Anderson Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to the Agreement and Plan of Merger (the "Merger Agreement"). Under the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). On the effective date and time of the Merger, all of the outstanding shares of the Issuer's Common Stock, the outstanding restricted stock units that were vested at the effective time of the Merger, the outstanding and unexercised warrants to purchase shares of the Issuer's Common Stock that provided for their deemed exercise as a result of the Merger, and the outstanding and unexercised options to purchase the Issuer's Common Stock or stock appreciation rights that were vested at the effective time of the Merger,
    2. (cont'd) in each case immediately prior to the effective time of the Merger, including the Common Stock and warrants owned by the Redmile Funds (as defined below) and the Common Stock owned by Redmile Group, LLC ("Redmile"), were cancelled and converted into the right to receive cash based on a purchase price of $2.35 per share in accordance with the Merger Agreement.
    3. The securities of the Issuer reported herein are directly owned by certain private investment vehicles managed by Redmile (each, a "Redmile Fund"), including RedCo II Master Fund, L.P. and Redmile Private Investments II, L.P. (the "Reporting Funds"), and may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of the Reporting Funds, Redmile and Mr. Green (collectively, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    4. The shares of Common Stock, Pre-Funded Warrants and Breakeven Warrants of the Issuer reported herein are owned directly by RedCo II Master Fund, L.P.
    5. The shares of Common Stock of the Issuer reported herein are owned directly by Redmile Private Investments II, L.P.
    6. The Pre-Funded Warrants are exercisable by the holder at any time until fully exercised at an exercise price of $0.0001 per share of the Issuer's common stock (the "Pre-Funded Warrant Share"), subject to a limitation on the right of the Issuer to issue the Pre-Funded Warrant Shares if and to the extent that such exercise would violate the rules or regulations of Nasdaq Stock Market LLC. The Pre-Funded Warrants have no expiration date.
    7. The Breakeven Warrants became exercisable upon the closing of the closing of the underwritten public offering on November 20, 2023. The Breakeven Warrants will expire on the seventh anniversary of the issuance date.
    Remarks:
    Robert Faulkner, a member of the Board of Directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. As of the Merger Date, Mr. Faulkner resigned from the Issuer's Board of Directors in connection with the Merger.
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC 10/04/2024
    /s/ Jeremy Green 10/04/2024
    By: /s/ Jeremy Green, Managing Member of RedCo II (GP), LLC, general partner of RedCo II Master Fund, L.P. 10/04/2024
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC, Managing Member of Redmile Private Investments II (GP), LLC, General Partner of Redmile Private Investments II, L.P. 10/04/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

      SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

      8/12/24 4:01:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/27/23 7:00:06 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/22/23 4:15:24 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Augmedix Inc.

      15-12G - Augmedix, Inc. (0001769804) (Filer)

      10/15/24 9:32:28 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:04 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:02 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Augmedix downgraded by Lake Street

      Lake Street downgraded Augmedix from Buy to Hold

      7/22/24 8:25:03 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

      7/22/24 8:02:58 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by Maxim Group with a new price target

      Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

      5/14/24 8:17:17 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Augmedix to Join Forces with Commure

      SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

      7/19/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

      SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

      5/29/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

      SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

      4/4/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

      SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

      5/13/24 4:03:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Augmedix Inc.

      SC 13G - Augmedix, Inc. (0001769804) (Subject)

      7/29/24 5:23:20 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      7/19/24 7:45:47 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:01:03 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Faulkner Robert C.

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 1:17:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary